Avacta Group PLC New OPTIM Software and Hardware
04 August 2014 - 4:01PM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
04 August 2014
4 August 2014
Avacta Group plc
("Avacta" or the "Group")
New OPTIM Software and Hardware
Avacta Group plc (AIM: AVCT), the global provider of proprietary
diagnostic tools, consumables and reagents for human and animal
healthcare, announces that Avacta Analytical has completed the
development of two new OPTIM variants. Alongside this, the Group
has released upgraded OPTIM software, intended to widen the range
of potential customers.
OPTIM, Avacta Analytical's protein characterisation instrument,
was launched during 2010 as OPTIM 1000 and was substantially
redeveloped into the OPTIM2 system during 2013. Designed to reduce
the time and cost of therapeutic protein development, the OPTIM
instruments can provide multiple protein stability-indications at
high speed using ultra-low sample volumes.
Avacta has completed the development of upgraded software for
the OPTIM platform, expanding the capabilities available to end
users. Two new variants to the core OPTIM platform, OPTIM 375 and
OPTIM 445, which incorporate incremental measurement capabilities
are now available. The Directors consider that these two new
variants and the related upgraded software widen the appeal of
OPTIM in its core drug development market by focusing on
applications to characterise the viscosity of samples and the
stability of membrane protein targets.
Alastair Smith, Avacta Group Chief Executive of Avacta said:
"Now that OPTIM is becoming established as a valuable tool for
protein stability characterisation, we are working hard to expand
the range of applications and measurement types that the system can
support in order to broaden the instrument's market appeal and
drive consumable usage. The latest developments are in response to
the market demand, which is growing worldwide, that we have
identified for viscosity determination on small samples and for
stability characterisation of membrane protein targets which are a
challenging but important class of protein samples."
Enquiries:
Avacta Group plc Tel: +44 (0) 844 414
Alastair Smith, Chief Executive Officer 0452
Tim Sykes, Chief Financial Officer www.avacta.com
Numis Securities Limited Tel: +44 (0) 207 260
Michael Meade / Freddie Barnfield - Nominated 1000
Adviser www.numiscorp.com
James Black - Corporate Broking
Media Enquiries Tel: +44 (0) 207 933
Walbrook PR Ltd 8780
Mike Wort / Anna Dunphy avacta@walbrookpr.com
About Avacta Group plc - www.avacta.com
Avacta Group plc is a global provider of innovative
technologies, consumables and reagents for the life science
markets, from drug discovery to diagnostics. Avacta operates
through three divisions:
Avacta Analytical High throughput analysis instrument, Optim,
www.avactaanalytical.com to help reduce the cost and risk of drug development.
Avacta Animal Health Veterinary diagnostics reference laboratory,
www.avactaanimalhealth.com diagnostic kits and newly launched in-clinic
blood analyser, Sensipod.
-------------------------------------------------------
Avacta Life Sciences Novel non-antibody affinity reagents called
www.avactalifesciences.com Affimers, with a wide range of Life Science
applications in diagnostics, drug and biomarker
discover and biotech research and development.
-------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMGGRKMZGDZM
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024